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Abstract TheMilieu Intérieur Consortium has established a 1000-person healthy population-based
study (stratified according to sex and age), creating an unparalleled opportunity for assessing the
determinants of human immunologic variance. Herein, we define the criteria utilized for participant
enrollment, and highlight the key data that were collected for correlative studies. In this report, we
analyzed biological correlates of sex, age, smoking-habits, metabolic score and CMV infection. We
characterized and identified unique risk factors among healthy donors, as compared to studies that
have focused on the general population or disease cohorts. Finally, we highlight sex-bias in the
thresholds used for metabolic score determination and recommend a deeper examination of current
guidelines. In sum, our clinical design, standardized sample collection strategies, and epidemio-
logical data analyses have established the foundation for defining variability within human immune
responses.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).rieur Consortium. Additional
ww.pasteur.fr/labex/milieu-1. Introduction
Susceptibility to infections, disease severity, and response to
medical therapies or vaccines are highly variable from one
individual to another. Medical practices and public health
policies typically take a ‘one size fits all’ model for disease
management and drug development. This approach ignores
individual heterogeneity in immune responses that likely
impacts the response to therapy or the efficiency and
development of side effects secondary to vaccine or treatment
administration. Due to the complexity of immune responses atthe individual and population level, it has been challenging
thus far to define the borders of a healthy immune system as
well as the parameters (genetic, epigenetic, and environmen-
tal) that drive its naturally-occurring variability. In particular,
such assessments require large sample sizes, consensus for
defining “healthy”, and standardized protocols for sample
recruitment. In this context, the Milieu Intérieur Consortium
initiated in September 2012 a cross-sectional healthy
population-based study called “Genetic & Environmental
Determinants of Immune Phenotype Variance: Establishing
a Path Towards Personalized Medicine (ID-RCB Number:
2012-A00238-35)”.
The overall aim of the Milieu Intérieur study is to assess
the factors underlying immunological variance within the
general healthy population. The primary objective is to
279The Milieu Intérieur study — An integrative approach for study of human immunological variancedefine genetic and environmental factors that contribute to the
observed heterogeneity in immune responses. This will be
realized by characterizing and integrating (i) every-day life
habits through an extensive questionnaire; (ii) genomic vari-
ability using genome-wide SNP genotyping and whole-exome
sequencing; (iii) metagenomic diversity based on sequence
analysis of bacterial, fungal and viral populations in fecal
and nasal samples; (iv) induced transcriptional and protein
signatures by whole microbes, microbial-associated molecular
pattern (MAMP) agonists, medically relevant cytokines, or
stimulators of the T cell response; and (v) variability in levels
of circulating immune cell populations based on flow
cytometry. The secondary objective is to establish a cell
bank, including EBV-transformed B cell lines and fibroblasts
from genetically annotated healthy individuals for use in
mechanistic studies. To achieve the above-mentioned objec-
tives, a total of 1000 healthy volunteers, descendants of
mainland French persons for at least three generations, split
equally by sex (1:1 sex ratio) and stratified across five-decades
of life were recruited.
Herein, we present the socio-demographic and biological
parameters that define our healthy donor cohort. Through
unbiased statistical approaches, we identified known sex-
and age-associated phenotypes, thus confirming the overall
integrity of the data and validating our population sample as
a reference for the healthy French population. Additional
analyses provided new insight into the definition and
risk factors of metabolic syndrome. Finally, we identified
dependent and independent variables among the collected
meta-data, results that will be applied to future association
studies. This unique healthy donor population study may
ultimately serve as a control reference sample for future
disease based studies.
2. Materials and methods
2.1. Study objectives
In the context of a French scientific initiative, financed
through the Investissement d'Avenir as part of a Laboratoire
d'Excellence (LabEx) research program, the Milieu Intérieur
Consortium was developed with the objective to define the
determinants of human immune variance.
2.2. Clinical protocol and implementation
The clinical study was approved by the Comité de Protection
des Personnes — Ouest 6 (Committee for the protection of
persons) on June 13th, 2012 and by the French Agence
nationale de sécurité du médicament (ANSM) on June 22nd,
2012. The study is sponsored by the Institut Pasteur (Pasteur
ID-RCB Number: 2012-A00238-35), and was conducted as a
single center study without any investigational product.
The protocol is registered under ClinicalTrials.gov (study#
NCT01699893).
Our strategy to define the parameters of a healthy
population included the gathering of a working group
composed of experts representing different clinical (medical
biology, regenerative medicine, allergy, pediatrics, nutrition,
psychiatry, lab medicine) and scientific (immunology, genet-
ics, epidemiology, methodology, sociology, gut microbiota)specialties to help establish the criteria for qualifying an
individual as a “healthy” donor while preserving the feasibility
of recruitment and permitting robust statistical analysis.
Specifically, this working group discussed the general eligibil-
ity criteria to pre-screen subjects (age, sex, BMI, self-reported
ancestry, relatedness with the other subjects) and identified
specific exclusion criteria thatmay impact the immune system
and/or study procedures (e.g., chronic diseases known to
involve the immune system, subjects with skin disorders that
would compromise skin biopsy, etc.). Known medical, physi-
ological, and behavioral factors with potential to affect
immune cell activities or the microbiota environment were
thoroughly reviewed and retained on the basis of their impact
on the objective of our project, while preserving the
feasibility of enrollment. We further considered the preva-
lence of donor characteristics, excluding those phenotypes
that are below 1% in the population (e.g., peanut allergy), to
ensure sufficient power for association studies. Efforts were
made to avoid the selection of individuals following too
conservative criteria (i.e., “super healthy” population), as
this would compromise the underlying purpose of the study. A
Scientific Advisory Board helped to develop and refine the
study protocol, donor information and consent forms. They
also provided oversight for ensuring consistency in screening,
enrollment, body site sampling, and compliance with regula-
tory and data management requirements.
Laboratory protocols were standardized and staff mem-
bers were trained in sample preparation protocols. Two risk
assessments audits were conducted during the training
period to refine sample handling and technical protocols.
The clinical study opened at the investigator site (Biotrial,
Rennes, France) on September 7th, 2012 and the first
sample was collected on September 17th, 2012. All subjects
provided informed consent prior to enrollment in the study.
Subjects received compensation for their participation.2.3. Subject screening and recruitment
A pre-existing donor database composed of ~110,000 donors
was used for pre-screening potential participants in accor-
dance with the study criteria. Additional advertising and
website recruitment campaigns were launched in order to
complete strata not sufficiently represented in the donor
database. Eligibility was assessed by telephone interview
and confirmed during a preliminary information meeting
about the objectives of the research. Interested participants
that met pre-screening criteria returned for the enrollment
visit (referred to as V0). During V0, eligibility criteria were
assessed in two stages: first, based on demographical data
and clinical examination; and second, by analysis of blood
and urine samples that were sent for clinical laboratory
testing (Table S1). During the course of their participation in
the Milieu Intérieur project, subjects were informed and
encouraged to participate in a non-interventional French
nutritional survey, Etude Nutrinet-Santé (www.etude-
nutrinet-sante.fr) [25].
Upon receiving the clinical laboratory results, and
confirming that all inclusion and exclusion criteria were
respected, all subjects were invited to return for the inclusion
visit (referred to as V1). Based on a defined randomization
strategy, 500 subjects participated in a second visit (referred
280 S. Thomas et al.to as V2) for repeat sampling (Fig. 1). V0 and V1were scheduled
with a 4–14 day interval; and V2 took place 14–42 days after
V1. Of those that were randomized for repeat collections, 340
donors consented for a skin biopsy at V1 (n.b. the number of
subjects with skin biopsy at V1 was restricted due to technical
constraints). The financial compensation for participating in V0
was 50€, 150€ for V1, 100€ for V2 and 50€ for the skin biopsy.
2.4. Cross-sectional study
The Milieu Intérieur sample is composed of 1000 healthy
volunteers, descendants of mainland French persons for at
least three generations, stratified according to sex with a
1:1 ratio (500 subjects by sex); and age (5 decades of age:
[20–29], [30–39], [40–49], [50–59] and [60–69] years, with
200 subjects per stratum). Subjects were randomized for a
single or repeated collection (50% per stratum returned for
V2). All donors were recruited by Biotrial Inc., a clinical
research organization (CRO) based in Rennes, France. From
September 17th, 2012 to August 8th, 2013, a total of 1238
donors were screened and 1012 healthy donors were
enrolled. Twelve donors withdrew, so the final sample
collection was composed of 1000 persons.
2.5. Inclusion/exclusion criteria
The study design concerned the definition of “healthy” in
accordance with the goal to maximize our ability to
associate genetic and epigenetic variation with defined
phenotypes. This was achieved by establishing a detailed list
of inclusion and exclusion criteria that ensured the recruit-
ment of volunteers with a minimally perturbed immuneFigure 1 Schematic representation of donor recruitment for the M
according to sex (500 men, 500 women) and age (200 donors per d
individuals at visit 0 (Enrollment). Of those screened, 226 donors w
(n = 54), past medical history (n = 67), identification of an exclusion
laboratory testing (n = 51) (see Fig. S1). An additional 16 donors wit
blood, fecal samples and nasal swabs were collected. Punch biopsies
subjects were randomly selected (stratified by age and sex) to return
and nasal swabs was performed. Detailed medical histories and ques
personnel using an electronic case report form.system. Briefly, donors could not have evidence of, or report
a history of neurological or psychiatric disorders, or severe/
chronic/recurrent pathological conditions. Other exclusion
criteria included: history or evidence of alcohol abuse,
recent use of illicit drugs (including cannabis), recent
vaccine administration, and recent use of immune modula-
tory agents. To avoid the influence of hormonal fluctuations
in women during the peri-menopausal phase, only pre- or
post-menopausal women were included. To avoid the
presence of population structure in our study population
(i.e., highly variable genetic backgrounds due to different
ancestry), which would impact upon the power to detect
genotype-to-phenotype associations, we restricted our study
to individuals of European-descent, i.e., French citizens
whose ancestry for three generations was of Metropolitan
French origin (i.e., the subject's parents and grandparents
were born in continental France).2.6. Physical and clinical laboratory testing
After initial evaluation for recruitment criteria, additional
physical examination and clinical laboratory testing were
performed at visit V0 in order to fully include the donors.
Donor BMI was restricted to ≥18.5 and ≤32 kg/m2. 20 mL of
blood sample (collected at V0 and V2, for repeat sampling)
was used for clinical chemistry, hematologic and serologic
assessments. A urinary human chorionic gonadotropin (hCG)
test was performed on female donors, and urine toxicology
screens for cannabinoid use, proteinuria and glycosuria were
conducted on all donors. All clinical laboratory assessments
were performed at the certified Laboratoire de biologie
médicale, Centre Eugene Marquis (Rennes, France).ilieu Intérieur study. To include 1000 healthy persons stratified
ecade of life, 20–69 years of age), we enrolled a total of 1238
ere considered non-eligible for reasons of consent withdrawal
criteria during the onsite physical examination (n = 54), or during
hdrew consent in the course of the study. During visit 1, whole
of the skin were obtained from 340 of these donors. Half of the
for a visit 2, when repeat sampling of whole blood, fecal samples
tionnaires were completed from all donors, recorded by medical
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serologies were performed on serum-separator tubes using
AU 400 Olympus, DXC 660 I, Advanced 2020, DXI (Beckman
Coulter), UF 50 Sysmex (Biomérieux) and Modular E170
(Roche) analyzers; Modular E170 (Roche), IRMA (Immunotech),
RIA (Labodia), and Hydrasys (Sebia) systems; and DXI immu-
noassay system (Beckman Coulter), respectively. Hematology
analysis were performed on EDTA tubes and coagulation tests
were performed on citrate tubes using LH750 (Beckman
Coulter) and STA-R (Stago) analyzers respectively.2.7. Sample collections and storage
Blood, nasal swabs and stool samples were collected from all
donors according to established protocols. For 500 individuals,
samples were collected at V1 only; and for the remaining 500
donors, samples were collected at V1 and V2 – separated by
14–42 days – thus providing validation samples to be used in
phenotypic studies. For donors randomized for two sample
collections, biopsies of the skin were performed once at V1, in
340 donors.
From each volunteer, 20 mL of blood was collected into 2
Na Heparin tubes, and 5 mL of blood into 1 EDTA tubes for
cytometric studies and banking of DNA, respectively. These
tubes were maintained at 18–25 °C, during daily transport
to Institut Pasteur (Paris), and processed within 6 h of
collection. An additional 50 mL of blood was collected using
a pre-heparinized large-bore syringe. This sample was
aliquoted into 40 — 1 mL TruCulture® tubes within 15 min
of collection. The TruCulture® systems were developed to
provide reproducible induction of innate or adaptive
immune responses and are described elsewhere [26]. After
stimulation, the liquid supernatants from the TruCulture®
tubes were aliquoted, and the cell pellet was stabilized in
Trizol. Both samples were stored at −80 °C.
Stool samples were collected in a double-lined sealable
bag with the outer bag containing a GENbag Anaer
atmosphere generator (Aerocult, Biomerieux), used to
maintain anaerobic conditions, and an anaerobic indicator
strip (Anaerotest®, Merck Millipore) to record maintenance
of the anaerobic atmosphere. Subjects were asked to
produce the fecal specimen at their home within 24 h
before their scheduled visits (V1, V2). Upon reception at the
clinical site, the specimen was aliquoted into cryotubes and
stored at −80 °C.
Nasal swabs were obtained with sterile, dry flocked swabs
(FLOQSwab™). Right and left nostrils were sampled sepa-
rately. All swabs were stored in stabilization media and
frozen at −80 °C.
Skin punch biopsies were performed under local anesthe-
sia. The biopsy was taken using a sterile single use biopsy
punch (7 mm * 3 mm round dermal punch). The material
collected was shipped the same day of the collection at 4 °C
to Genethon (Evry, Ile de France, France) where human
fibroblast cell lines were generated and aliquots stored.
The processing of each donor involved the production and
registration of more than 180 tubes. To ensure effective
traceability of all samples, a customized software system
was developed for managing 2D barcoded tubes. A central
sample database has been established to aggregate all
sample information for each donor, visit, and sample type.2.8. Case report forms
Detailed medical histories and questionnaires collecting
general information about socio-demographic, lifestyle and
family health history were recorded in an electronic case
report form. For example, the questionnaire collected
information concerning family status, income, occupational
status and educational level, smoking habits, alcohol intake,
sleeping habits, depressive symptoms, family medical
history and nutritional behavior and habits (for details, see
supplementary material: case report forms).2.9. Statistical analyses
Statistical analysis was performed using the Open Source R
Software, version 3.0.1 [27]. All statistical graphics were
generated using the ‘ggplot2’ package, version 0.97 [28].
The hierarchical clustering of our continuous explanatory
variables was based on the Spearman's correlation score (Rs)
using the ‘hclust’ function available from the base functions.
Random Forest (RF) models [2] were built using the
‘randomForest’ package (version 4.6–7). For each RF
model built (sex, age categories, smoking status) a forest
of 1000 trees was computed, and the ‘mtry’ parameter was
set to be the square root of the number of available
explanatory variables. When investigating outliers in our
sample, we used a z-score based criterion. For a given
metric, we considered a donor as an outlier if its measure-
ment was 3 standard deviations away for the mean of the
whole sample. Principal component analysis (PCA) on the
outlier cases of our dataset was performed with the
‘FactoMineR’ package version 1.25. Regression analyses were
conducted using the glm function in R. Levels of immunoglob-
ulins were log-transformed and standardized, prior to regres-
sion analyses. The representative nature of the cohort was
assessed by stratified sampling: 500 individuals were
sampled 10,000 times among all cohort participants, in
order to match the proportions of males and females and of
10-decades age groups observed in the general population.
Public data from the Institut National de la Statistique et
des Etudes Economiques (INSEE; National Institute of
Statistics and Economic Studies) were retrieved for the
entire Ille-et-Vilaine French department and the city of
Rennes (http://www.insee.fr/en/default.asp).3. Results
3.1. Sample and data overview
From September 17th, 2012 to August 8th, 2013, a total
of 1238 donors were screened and 1012 healthy donors
were enrolled (Fig. 1). The reasons for excluding the 226
pre-screened donors included withdrawal of consent (n = 54),
as well as medical history (n = 67), physical exam findings
(n = 54) or laboratory test results (n = 51) that were not in
accordance with the defined inclusion or non-exclusion
criteria (Fig. S1, Table S1). Questionnaires were completed
and clinical laboratory testing was performed at visit V0
(Tables 1–2, Tables S1–3). Among those enrolled, 12 donors
withdrew consent during the collection phase of the protocol.
282 S. Thomas et al.This resulted in a final set of 1000 subjects, with all donors
having completed an evaluation at visit V1 and 50% of them
(500 subjects) returning for evaluation at visit V2. During V1,
340 had a skin biopsy.
Donor recruitment was conducted in the vicinity of the
city of Rennes, in the Ille-et-Vilaine French region. We first
compared the socio-economic characteristics of the Milieu
Intérieur cohort to those of the general population of this
region (Table S4), after adjustment to match regional age
and sex stratification (see Methods section). We observed
~10% higher unemployment levels in the Milieu Intérieur
cohort (16.9% with 95% confidence interval (CI) [14.7%–
19.1%]), when compared to the Ille-et-Vilaine region or theTable 1 Sample collections obtained from study subjects.
Whole blood collection
CLT a Complete blood count: RBC count, HCT, HGB, MCV, MCH, W
LYMPHO, EOS, BASO, PLT count
CLT Blood electrolytes: Na, K, Ca, P, Cl, HCO3
CLT Liver function tests: HSA, ALP, AST, ALT, GGT, BILI, TPROT
CLT Inflammation: CRP
CLT Renal function tests: BUN, CREAT, UA
CLT Lipids/metabolism: GLUC, TCHOL, LDL, HDL, TRIGLY
CLT Serology: HBV (HBs Ag), HCV (anti HCV IgG, viral load if Ab+)
(anti-CMV IgG), HTLV-1 (anti-HTLV-1 IgG), influenza (anti-In
CLT Immunoglobulin electrophoresis: serum immunoglobulin con
IGE)
R b Immunophenotyping (Na Heparin tube): cytometric analysis
cells in circulation
R Functional immune stimulation (Na Heparin syringe): TruCu
R Genetic tests (EDTA tube): TruCulture tubes ×40
Urine collection
CLT Biochemistry: proteinuria, glycosuria (dipstick)
CLT Pregnancy test: bHCG concentration (women only)
CLT Toxicology: cannaboids
Fecal sample collection
R Enterotyping: bacterial, viral, fungal strains
Nasal swab
R Enterotyping: bacterial, viral, fungal strains
Biopsy
R Punch biopsy of skin
a CLT, clinical laboratory test; RBC, red blood cell; HCT, hematocri
corpuscular hemoglobin; WBC, white blood cell, NEUTRO, neutroph
platelet; Na, sodium; K, potassium; Ca, calcium; P, phosphorus; Cl,
alkaline phosphate; AST, aspartate aminotransferase; ALT, alanine
bilirubin; TPROT, total protein; CRP, C-reactive protein; BUN, blood
TCHOL, total cholesterol; LDL, low density lipoprotein; HDL, high dens
hepatitis C virus; HIV, human immunodeficiency virus; CMV, cyto
beta-human chorionic gonadotropin.
b R, Research tests.city of Rennes (6.0% and 8.2%, respectively) (Table S5). The
cohort also contained a higher proportion of retired persons
(16.6% [15.1%–17.9%] versus 8.1% and 4.9%) (Table S5).
Among employed people, socio-professional categories of
the Milieu Intérieur donors were biased towards more
employees and fewer laborers. We also observed that the
educational level of the Milieu Intérieur donors was
generally higher. Finally, 42.5% [39.5%–45.4%] of partici-
pants were renters, a value that is intermediate between
those of the Ille-et-Vilaine region and the city of Rennes
(33.1% and 59.5%, respectively) (Table S5), consistent with
the fact that donors reside in Rennes as well as in
surrounding areas.Visit 0 Visit 1 Visit 2
20 mL 87 mL 83 mL
BC count, NEUTRO, MONO, X X
X
X
X X
X
X
, HIV (anti-HIV IgM, IgG), CMV
fluenza IgG)
X
centrations (IGM, IGG, IGA, X
for major subsets of immune X X
lture tubes ×40 X X
X
N5 mL N5 mL
X
X X
X
N100 g N100 g
X X
2 swabs 2 swabs
X X
7 mm punch
X (n = 340)
t; HGB, hemoglobin; MCV, mean corpuscular volume; MCH, mean
il; LYMPHO, lymphocyte; EOS, eosinophil; BASO, basophil; PLT,
chloride; HCO3, bicarbonate; HSA, human serum albumin; ALP,
aminotransferase; GGT, gamma-glutamyl transpeptidase; BILI,
urea nitrogen; CREAT, creatinine; UA, urinalysis; GLUC, glucose;
ity lipoprotein; TRIGLY, triglycerides; HBV, hepatitis B virus; HCV,
megalovirus; HTLV, human T cell lymphotropic virus; βHCG,
Table 2 Socio-demographic information for study subjects.
Total
(n = 1000)
Male
(n = 500)
Female
(n = 500)
20–29
years
(n = 200)
30–39
years
(n = 200)
40–49
years
(n = 200)
50–59
years
(n = 200)
60–69
years
(n = 200)
Donor characteristics n % n % n % n % n % n % n % n %
BMI ⁎
18 b BMI ≤ 25 635 63.5 283 56.6 352 70.4 160 80 135 67.5 128 64 111 55.5 101 50.5
25 b BMI ≤ 30 300 30 181 36.2 119 23.8 34 17 55 27.5 54 27 72 36 85 42.5
30 b BMI ≤ 32 65 6.5 36 7.2 29 5.8 6 3 10 5 18 9 17 8.5 14 7
Total 1000 100 500 100 500 100 200 100 200 100 200 100 200 100 200 100
Education §
No diploma 38 3.8 20 4 18 3.6 6 3 4 2 10 5 10 5 8 4
Primary school certificate only 46 4.6 22 4.4 24 4.8 0 0 1 0.5 1 0.5 11 5.5 33 16.5
CAP, BEP, apprenticeship
certificate, BEPC (High school
diploma equivalent)
332 33.2 170 34 162 32.4 34 17 47 23.5 84 42 84 42 83 41.5
Baccalaureate or technician’s
certificate
268 26.8 130 26 138 27.6 64 32 65 32.5 44 22 50 25 45 22.5
Higher education (no professional
degree)
156 15.6 75 15 81 16.2 49 24.5 36 18 31 15.5 26 13 14 7
Higher education (Masters, PhD,
engineer’s diploma, MD, etc.)
160 16 83 16.6 77 15.4 47 23.5 47 23.5 30 15 19 9.5 17 8.5
Total 1000 100 500 100 500 100 200 100 200 100 200 100 200 100 200 100
Employment
Steady job 510 51 247 49.4 263 52.6 75 37.5 148 74.0 155 77.5 118 59 14 7
Unemployed 158 15.8 91 18.2 67 13.4 38 19 43 21.5 37 18.5 34 17 6 3
Student 74 7.4 41 8.2 33 6.6 71 35.5 3 1.5 0 0 0 0 0 0
Looking for first job 16 1.6 5 1.0 11 2.2 14 7 1 0.5 1 0.5 0 0 0 0
Housewife/househusband 21 2.1 2 0.4 19 3.8 2 1 4 2.0 5 2.5 8 4 2 1
Retired 215 21.5 114 22.8 101 20.2 0 0 0 0.0 2 1 40 20 173 86.5
NA 6 0.6 0 0.0 6 1.2 0 0 1 0.5 0 0 0 0 5 2.5
Total 1000 100 500 100 500 100 200 100 200 100 200 100 200 100 200 100
Full-time 406 40.6 219 43.8 187 37.4 65 32.5 115 57.5 122 61 96 48 8 4
Part-time 135 13.5 38 7.6 97 19.4 28 14 38 19 36 18 24 12 9 4.5
Not answered 459 45.9 243 48.6 216 43.2 107 53.5 47 23.5 42 21 80 40 183 91.5
Total 1000 100 500 100 500 100 200 100 200 100 200 100 200 100 200 100
Exclusively during the day 369 36.9 155 31 214 42.8 59 29.5 102 51 110 55 86 43 12 6
Exclusively during the night 36 3.6 12 2.4 24 4.8 7 3.5 10 5 10 5 8 4 1 0.5
Without fixed hours 135 13.5 90 18 45 9 27 13.5 41 20.5 37 18.5 26 13 4 2
Not answered 460 46 243 48.6 217 43.4 107 53.5 47 23.5 43 21.5 80 40 183 91.5
Total 1000 100 500 100 500 100 200 100 200 100 200 100 200 100 200 100
Socio-professional category
Farmer 10 1 6 1.2 4 0.8 1 0.5 2 1 1 0.5 2 1 4 2
Artisans. tradesman or company
director
46 4.6 36 7.2 10 2 4 2 11 5.5 10 5 7 3.5 14 7
Senior executive or independent
profession
42 4.2 29 5.8 13 2.6 1 0.5 15 7.5 4 2 7 3.5 15 7.5
Middle management 113 11.3 59 11.8 54 10.8 3 1.5 16 8 27 13.5 28 14 39 19.5
Employee 507 50.7 197 39.4 310 62 82 41 116 58 115 57.5 106 53 88 44
Labourer 100 10 76 15.2 24 4.8 11 5.5 19 9.5 19 9.5 27 13.5 24 12
Other categories (e.g. artist.
clergy. soldier. police officer)
60 6 48 9.6 12 2.4 7 3.5 11 5.5 18 9 15 7.5 9 4.5
Not answered 122 12.2 49 9.8 73 14.6 91 45.5 10 5 6 3 8 4 7 3.5
(continued on next page)
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Table 2 (continued)
Total
(n = 1000)
Male
(n = 500)
Female
(n = 500)
20–29
years
(n = 200)
30–39
years
(n = 200)
40–49
years
(n = 200)
50–59
years
(n = 200)
60–69
years
(n = 200)
Donor characteristics n % n % n % n % n % n % n % n %
Total 1000 100 500 100 500 100 200 100 200 100 200 100 200 100 200 100
Monthly income of the household
0 b salary ≤1000 158 15.8 75 15 83 16.6 78 39 16 8 21 10.5 23 11.5 20 10
1000 b salary ≤ 2000 340 34 160 32 180 36 73 36.5 75 37.5 70 35 60 30 62 31
2000 b salary ≤ 3000 256 25.6 134 26.8 122 24.4 27 13.5 59 29.5 50 25 59 29.5 61 30.5
3000 b salary ≤ 4000 164 16.4 82 16.4 82 16.4 12 6 41 20.5 43 21.5 34 17 34 17
4000 b salary ≤ 5000 59 5.9 35 7 24 4.8 8 4 4 2 12 6 17 8.5 18 9
5000 b salary 17 1.7 11 2.2 6 1.2 1 0.5 2 1 4 2 6 3 4 2
Not answered 6 0.6 3 0.6 3 0.6 1 0.5 3 1.5 0 0 1 0.5 1 0.5
Total 1000 100 500 100 500 100 200 100 200 100 200 100 200 100 200 100
Family status
Single with no children 320 32 155 31 165 33 108 54 45 22.5 42 21 56 28.0 69 34.5
Single with children 87 8.7 30 6 57 11.4 4 2 23 11.5 29 14.5 25 12.5 6 3
In couple but no children 259 25.9 142 28.4 117 23.4 58 29 22 11 27 13.5 48 24.0 104 52
In couple with children 328 32.8 172 34.4 156 31.2 24 12 110 55 102 51 71 35.5 21 10.5
Not answered 6 0.6 1 0.2 5 1 6 3 0 0 0 0 0 0 0 0
Total 1000 100 500 100 500 100 200 100 200 100 200 100 200 100 200 100
Housing
Owner 584 58.4 286 57.2 298 59.6 30 15 116 58 140 70 144 72 154 77
Renter 401 40.1 209 41.8 192 38.4 157 78.5 83 41.5 59 29.5 56 28 46 23
Not answered 15 1.5 5 1 10 2 13 6.5 1 0.5 1 0.5 0 0 0 0
Total 1000 100 500 100 500 100 200 100 200 100 200 100 200 100 200 100
Sport activities
Little or no physical activity 274 27.4 124 24.8 150 30 71 35.5 67 33.5 54 27 52 26 30 15
Moderate physical activity 656 65.6 314 62.8 342 68.4 110 55 115 57.5 133 66.5 139 69.5 159 79.5
Intensive physical activity
(competitions)
70 7 62 12.4 8 1.6 19 9.5 18 9 13 6.5 9 4.5 11 5.5
Total 1000 100 500 100 500 100 200 100 200 100 200 100 200 100 200 100
Smoking (cigarettes)
Non smoker 526 52.6 233 46.6 293 58.6 112 56 96 48 94 47 109 54.5 115 57.5
Former smoker 265 26.5 151 30.2 114 22.8 20 10 48 24 65 32.5 59 29.5 73 36.5
Smoker 209 20.9 116 23.2 93 18.6 68 34 56 28 41 20.5 32 16 12 6
Total 1000 100 500 100 500 100 200 100 200 100 200 100 200 100 200 100
Alchool
Never 91 9.1 43 8.6 48 9.6 12 6 24 12 26 13 16 8 13 6.5
Occasionally 523 52.3 220 44 303 60.6 96 48 104 52 108 54 111 55.5 104 52
Once per week 196 19.6 110 22 86 17.2 58 29 39 19.5 29 14.5 40 20 30 15
Several times per week 154 15.4 100 20 54 10.8 34 17 31 15.5 34 17 24 12 31 15.5
Everyday 36 3.6 27 5.4 9 1.8 0 0 2 1 3 1.5 9 4.5 22 11
Total 1000 100 500 100 500 100 200 100 200 100 200 100 200 100 200 100
Feeding at birth
Breastfed milk 286 28.6 137 27.4 149 29.8 66 33 47 23.5 49 24.5 61 30.5 63 31.5
Formula milk 465 46.5 199 39.8 266 53.2 82 41 113 56.5 108 54 87 43.5 75 37.5
Not known 246 24.6 163 32.6 83 16.6 52 26 40 20 42 21 51 25.5 61 30.5
Not answered 3 0.3 1 0.2 2 0.4 0 0 0 0 1 0.5 1 0.5 1 0.5
Total 1000 100 500 100 500 100 200 100 200 100 200 100 200 100 200 100
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Table 2 (continued)
Total
(n = 1000)
Male
(n = 500)
Female
(n = 500)
20–29
years
(n = 200)
30–39
years
(n = 200)
40–49
years
(n = 200)
50–59
years
(n = 200)
60–69
years
(n = 200)
Donor characteristics n % n % n % n % n % n % n % n %
Contraception †
Intrauterine device (IUD) 72 14.4 7 7 29 29 29 29 7 7 0 0
Oral Contreception 117 23.4 55 54 37 37 20 20 5 5 0 0
Male or female condomn 94 18.8 29 28 26 26 32 32 7 7 0 0
Tubal ligation 7 1.4 0 0 2 2 5 5 0 0 0 0
Other method of contraception 14 2.8 7 7 3 3 2 2 2 2 0 0
None 13 2.6 4 4 3 3 5 5 1 1 0 0
Not answered (or not asked) 183 36.6 0 0 0 0 7 7 78 78 100 100
Total 500 100 102 100 100 100 100 100 100 100 100 100
⁎ Study inclusion criteria set limits for BMI.
§ The certificat d'études primaires (CEP) was a diploma awarded at the end of elementary primary education in France (from 11 to 13
years inclusive until 1936) and certifying that the student had acquired basic skills in writing, reading, mathematics, history, geography
and applied sciences. It was officially discontinued in 1989.
† Questions were posed to pre-menopausal women only. Multiple choice was allowed.
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habit- associated biological parameters
A total of 328 variables were obtained from the study
questionnaire (see Case Report Form). The physical exam-
ination and clinical laboratory analyses were assembled into
a data warehouse using LabKey [1]. To validate the data
collected in our study, we first tested our ability to identify
known biological correlates of sex, age or smoking-habits. To
achieve this, we utilized a discovery-based approach. With
the initial aim of reducing the complexity of the biochem-
ical, hematologic and serologic data – thereby increasing
the power of our association studies – we correlated all
quantitative values from clinical laboratory data for the
1000 donors to each of the other variables using a
Spearman's correlation matrix. Results were clustered and
plotted using a dendrogram to represent the relationships
between variables, with height (ordinate axis) being
inversely related to the correlation coefficient (Fig. 2A).
For pairs or groups of variables that showed high correlation
(height b 0.3, equivalent to rs N 0.67), we selected one
representative variable (indicated by red star). Next, we
utilized the standard machine learning Random Forest (RF)
approach [2], applied to the dataset in order to identify the
variables that are most important to correctly classify
donors based on sex (Fig. 2B) or age (Fig. 2C). Of note,
bootstrap aggregation (also referred to as bagging) of data
was selected due to its stability and accuracy in statistical
classification and regression. This approach, which reduces
variance and avoids overfitting, can be applied to a variety
of binary data (e.g., male vs. female) and continuous
variables (e.g., age). Using this method, we found that
serum creatinine (CREAT) concentration, hematocrit (HCT)
and height are the features that are most predictive of sex;
and lower glomerular filtration rate (GFR), higher plasma
low density lipoprotein (LDL) concentration and higher
systolic blood pressure (SYSBP1) to be most associated withage. These results were validated using univariate tests
(Table S3) and representative box-plots are shown for the
most significant variables (Figs. 2D, E).
To assess other determinants, while controlling for sex-
and age-associated effects on clinical laboratory data, we
used a linear regression model, considering sex and age as
independent covariates. This permitted us to examine the
features predictive of smoking habits, again employing
Random Forest analysis to segregate non-smokers, not
exposed to second-hand smoke (n = 394) from active
smokers (n = 208) present in our sample (Fig. 3A). Validating
prior findings [3–6], we report that serum IgG and bilirubin
concentrations were lower in smokers as compared to
non-smokers (Figs. 3A, B); whereas monocyte, neutrophil
and lymphocyte numbers were higher in smokers as
compared to non-smokers (Figs. 3A, C). These observations
may be related to lower antioxidant concentrations [7], and
a diminished adherence of leucocytes to blood vessel walls
[8]. Interestingly, a comparison of non-smokers and prior
smokers present in our sample (n = 251) indicates that
smoking cessation restores the biochemical and immunolog-
ical phenotypes associated with non-smokers (Figs. 3B, C).
Together, these data highlight that our sample population
can be used to study associations in the general French
population and can be compared to prior study cohorts.3.3. Smoking habits confer increased risk for
metabolic syndrome among healthy donors
Over the past two decades, there has been increasing concern
about the prevalence of obesity and its association with
diabetes and cardiovascular disease (CVD), and their link to
metabolic syndrome [9]. While several assessment scores have
been established, the metabolic syndrome score is now a
widely applied measure. Metabolic syndrome is most common-
ly defined by six variables: increased abdominal circumference
286 S. Thomas et al.(AbdoCM N 94cm European men, N 80cm European women),
elevated systolic blood pressure (SYSBP ≥ 130mmHg), elevated
diastolic blood pressure (DYSBP ≥ 85mmHg), elevated
triglyceride levels (TG ≥ 1.7mM), diminished levels of highdensity lipoprotein (HDL b 1 mM men, b 1.3 mM women) and
glucose concentration (≥ 6.1 mM) [10]. We thus analyzed
donors for these six criteria, using accepted cut-values for
European men and women, and for each criterion, data was
Figure 3 Tobacco use associatedwith lower IgG, bilirubin concentrations and higher number of circulatingmonocytes, neutrophils and
lymphocytes. (A) The same variables selected from Fig. 2A were regressed for sex and age, then subjected to Random Forest analysis to
identify variables that discriminate active smokers (n = 208) from non-smokers with no reported passive smoking (n = 394). The random
forest classification had an estimated error rate of 24.5% on the out-of-bag error. Variables are reported according to their impact on the
out-of-bag error (percentage of mean decrease accuracy). (B, C) The top variables found to be lower (B) or higher (C) in smokers as
compared to non-smokers are shown, with the inclusion of ex-smokers with no reported passive smoking (n = 201) as an additional group.
Variables that measured importance through permutation are depicted: serum IgG concentration (IGG, g/L); bilirubin concentration
(BILI, μM); the absolute number of monocytes (MONO, ×103/μL), neutrophils (NEUTR, ×103/μL) and lymphocytes (LYMPH, ×103/μL).
Individual donors are represented by an open black circle. The data is overlaid by boxplots that represent the set of donors tested; the
median value is indicated by the black bar, the lower and upper edges correspond to the first and third quartiles (the 25th and 75th
percentiles), respectively, and the whiskers extend to the highest/lowest value that is within 1.5x interquartile range (IQR). A student
t-test was used to determine statistical differences between two groups for the given variables (p-value indicated and bracket defining
the two groups being compared, *, p b 0.05; ***, p b 0.001; ns, not significant).
Figure 2 Unbiased assessment of the clinical laboratory data revealed expected sex-, and age-associations. (A) Biological
measurements from the electronic case report forms (eCRF) and clinical laboratory data were evaluated using Spearman's correlation
matrix and plotted using a dendrogram. For subsequent data mining, representative variables were selected (red star) from pairs or
groups of factors showing high correlation (height b 0.3, indicated by dotted red line). (B, C) Random Forest method was employed to
identify variables that discriminate men and women (B) or age, used as a continuous variable (C). The random forest classification on
sex indicated an estimated error rate of 2.4% based on the out-of-bag error, while the random forest regression on age had a mean of
squared residuals of 95.1, with 54% variance explained. Variables are reported according to their impact on the out-of-bag error
(percentage of mean decrease accuracy). (D, E) The top two variables for sex (D) or age (E) that measured importance through
permutation are depicted: creatinine concentration (Creat, μM); hematocrit (HCT, %); glomerular filtration rate (GFR, mL/min); and
low density lipoprotein concentrations (LDL, mM). Individual donors are represented by an open circle (blue, men; red, women). The
data is overlaid by boxplots that represent the set of donors tested; the median value is indicated by the black bar, lower and upper
edges correspond to the first and third quartiles (the 25th and 75th percentiles), respectively, and the whiskers extend to the
highest/lowest value that is within 1.5x interquartile range (IQR); and a student t-test was used to determine statistical differences
between men and women for the given variables (p-value indicated at the top of each graph) (D). Regression lines indicate the
respective curve for men and women and results of univariate statistical analyses can be found in Table S2 (E).
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288 S. Thomas et al.reported in relation to sex and age (Fig. 4A). Notable
differences in the diastolic, systolic blood pressure, triglycer-
ide and glucose levels were observed, with men having
significantly higher levels than women (n.b., comparisons
were made for those criteria in which reference values were
similar between men and women). In all instances, biologic
measures showed a significant increase with advancing age.
Quantitative laboratory data were again regressed out for sex
and age effects, and the component variables were evaluated
among smokers, ex-smokers and non-smokers (Fig. 4A).To generate a composite metabolic score, 1 point was
assigned for each of the assessed variables, taking blood
pressure elevation as a single value (i.e., elevated SYSBP
and/or DIASBP = 1 point) [11]. The index value for the
metabolic score indicated that 400 individuals (40%) had at
least one positive criterion, 155 donors (15.5%) had a score
of 2, and 53 donors (5.3%) had a score of ≥ 3, despite
meeting all criteria for being a healthy donor (Fig. 4B).
Notably, women had a higher probability of scoring ≥ 1 due
to the low threshold for abdominal circumference for
289The Milieu Intérieur study — An integrative approach for study of human immunological varianceEuropean women (299 women vs. 135 men being above the
respective abdominal circumference cut value) (Table S6).
Indeed all variables that constitute the metabolic score,
with the exception of HDL, showed a sex bias (Fig. S2). As a
result, we observed a significant association between sex
and the metabolic index (χ2 = 43.1, degrees of freedom
(df) = 3, p = 2.3 × 10−9; Fig. 4B); and there was a significant
increase in median age when donors were stratified based on
metabolic index (χ2 = 87.9, df = 12, p = 2.3 × 10−13,
Fig. 4C). While smoking habits did not impact each of the
individual variables, there was a significant relative risk
increase associated with smoking as compared to
non-smokers, after regressing out sex and age (Fig. 4D,
χ2 = 13.1, df = 3, p b 0.005; Table S6). Thus, smoking habits
are an independent risk factor for the metabolic syndrome,
distinct from its known association with CVD.3.4. Sex, age and relationship status are risk factors
for altered immunological status
Common infections and abnormal levels of immunoglobulins
are conditions that may alter the immunological state of
individuals. In our study population, circulating levels of
immunoglobulins (i.e., IgM, IgG, IgE and IgA) were quantified,
as well as influenza- and cytomegalovirus (CMV)- specific IgG
antibodies (Table S3). We investigated association of demo-
graphic, socio-economic variables and/or lifestyle habits with
these serological parameters (Table 2). Regression analyses
were used to identify independent predictors among the 73
available variables.
Using univariate regression analysis, we found that positive
detection of anti-influenza virus IgG was significantly associ-
ated with higher stature (p = 5.7 × 10−4), sex (incidence of
86.1% and 77.8% in men and women; p = 1.0 × 10−3), a higher
weight (p = 2.1 × 10−3) and a younger age (p = 2.3 × 10−2).
However, only sex and age remained significantly associated
with influenza specific IgG when multiple regression analyses
were performed, including sex, age, height and weight
predictors (p = 1.1 × 10−3, 2.4 × 10−2, 0.85 and 0.17,
respectively). Similarly, when stratifying by sex, parameters
such as height and weight were no longer associated withFigure 4 Among healthy donors, being a male, increasing age and
score index value. (A) Variables that are used for determining an in
differences between men and women; across age, as a continuous
variables included abdominal circumference (AbdCM, cm), systolic b
mm Hg), glucose levels (mM), high density lipoprotein concentratio
depiction of sex and age associations, individual donors are represent
associations, data was regressed for sex and age, data is plotted a
represented by an open black circle. Dotted black lines indicate r
sex-dependent reference indicators are used (blue dotted line, m
calculated for each donor and plotted to represent number of donor
and women (red). (C) Age association with metabolic score index va
women (red circles) in the bottom plot. (D) Contingency tables are s
reported. The data is overlaid by boxplots that represent the set of d
lower and upper edges correspond to the first and third quartiles (
extend to the highest/lowest value that is within 1.5x interquartile
determine statistical differences between two groups for the given v
being compared, *, p b 0.05; **, p b 0.01; ns, not significant).anti-influenza virus IgG (p N 0.05). More interestingly, a
younger age was found to be associated with infection only
in women (pwomen = 7.8 × 10−3 vs. pmen = 0.91). Indeed, the
sex ratio in IgG-samples was 0.90 in individuals between 20
and 39 years, while it dropped to 0.53 in people between 40
and 69 years. Together, and in accordance with previous
findings [12], our analyses support the notion that men are at
higher risk of being positive for anti-influenza IgG, and
suggests a female-specific influence of age on influenza
infection.
Conversely, factors associated with positive detection of
anti-CMV IgG were an older age (p = 7.6 × 10−7), the
consumption of raw fruits and vegetables (p = 4.0 × 10−4 and
p = 1.6 × 10−4, respectively), being female (p = 1.7 × 10−3),
a shorter sleep duration (p = 1.5 × 10−3), single status (p =
5.8 × 10−3) and a lower stature (p = 1.0 × 10−2), by univariate
regression analysis. All these factors remained significantly
associated in a multiple regression analysis, with the excep-
tion of height and the consumption of raw fruits (Table S7).
While age was consistently associated with CMV infection in
both men and women (pmen = 2.1 × 10−2 and pwomen =
3.8 × 10−3), consumption of raw vegetables (pmen = 0.59 and
pwomen = 8.2 × 10−3), relationship status (pmen = 0.48 and
pwomen = 4.6 × 10−3) and hours of sleep (pmen = 0.13 and
pwomen = 7.7 × 10−2) were significant (or trended towards
significance) in women only. By contrast, the association of
CMV infection with being single in men was restored when
restricting the analysis to men who have children (pmen =
1.9 × 10−2; Fig. S2).
Next, the different classes of immunoglobulins were
evaluated for their association with available demographic
data, using multiple regression of the most significant
univariate predictors. Elevated IgG levels were associated
with smoking (p = 1.2 × 10−13; Fig. 3), influenza virus
infection (p = 5.2 × 10−4), multivitamins consumption (p =
8.2 × 10−3) and being a woman (p = 3.1 × 10−2). The three
former factors remained significant (or trended towards
significance) in males and females, when considered
separately. Elevated IgM levels were associated with being
a woman (p = 5.0 × 10−4) and with lower BMI (p = 1.8 × 10−2).
Elevated IgE levels were associated with being a man (p =
1.4 × 10−6), younger age (p = 1.4 × 10−3), exposure to silicatobacco use are independent risk factors for higher metabolic
dividual's metabolic score are plotted individually, representing
variable; or among non-smokers, ex-smokers and smokers. The
lood pressure (SysBP, mm Hg), diastolic blood pressure (DysBP,
n (HDL, mM), and triglyceride concentrations (Trigly, mM). For
ed by an open circle (blue, men; red, women). For smoking habit
s relative units for respective plots, and individual donors are
eference values for European population; and where relevant
en; red dotted line, women). (B) The metabolic score was
s having indicated index values. Bar graphs indicate men (blue)
lues is shown, indicating men (blue circles) in the top plot, and
hown for indicated comparisons and results from χ2 testing are
onors tested; the median value is indicated by the black bar, the
the 25th and 75th percentiles), respectively, and the whiskers
range (IQR) (A, C). Where indicated a student t-test was used to
ariables (p-value indicated and bracket defining the two groups
290 S. Thomas et al.(p = 1.0 × 10−2), smoking (p = 4.7 × 10−2), and a familial
history of atopy (p = 5.0 × 10−2). When stratifying these
analyses by sex, exposure to silica was significant in menFig. 5 Outlier data maps primarily to liver function tests and co
structure based on measured variables. (A) For each donor, and fo
z-score criteria. An aggregated score was computed for each donor t
as an outlier. The distribution of aggregated outlier cases among ou
(B, C) A Principal Component Analysis (PCA) on 62 donors presenting
projection of the donors onto the plane composed of the first 2 p
cumulative variance from the principal components is represented
represented the number of donors that had been flagged as an abo
left). (E) The absolute number of eosinophils is represented for V1 a
Values have been regressed-out to take into consideration age and
dotted line depicts the theoretical ideal correlation between the
threshold, respectively, as defined by our z-score based outlier de
relationship between the eosinophil count and IgE level is shown. Bo
and sex effects. Individual donors are represented by a black dot.
respectively, as defined by our z-score based outlier detection. Theonly (pmen = 4.6 × 10−3 and pwomen = 0.48). Finally, elevated
IgA levels were associated with an older age (p = 5.3 × 10−5),
being aman (p = 5.5 × 10−3) and non-smoking (p = 2.1 × 10−2).mplete blood count measurements, yet shows now underlying
r each measurement, an outlier status was assessed based on a
o represent the number of times a given donor had been flagged
r cohort is shown. Colors indicate sex (men, blue; women, red).
N2 outlier cases has been performed. The scatterplot shows the
rincipal components, capturing 18.8% of the variance (B). The
(C). (D) For each measurement considered in our analysis, we
ve-the-range (on the right), or below-the-range outlier (on the
nd V2, shown as representative data for the measured variables.
sex effects. Individual donors are represented by a black dot. A
2 visits. Dotted blue and red lines show the lower and upper
tection. The green line shows the mean measurement. (F) The
th values have been regressed-out to take into consideration age
Blue and red dotted lines show the lower and upper threshold,
green line shows the mean measurement.
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among the measured variables
Despite the stringent criteria used for the recruitment of
healthy donors (Table S1), we observed donors presenting
extreme values within the observed range of biological
measures. We identified 241 donors (24.1%) with clinical
laboratory values that were outliers with respect to at least
one variable, as defined by z-score based criteria (Fig. 5A).
In only 66 individuals (6.6%), we observed two or more
outlier events (Fig. 5A). To assess possible structure among
the outlier events, we analyzed the data from those 66
individuals with outlier values for one or more laboratory
tests, and projected the data using principal component
analysis (PCA) (Fig. 5B). The dataset showed a lack of
structure, which could also be observed by the broad
distribution of variance across the top 35 component axes
(Fig. 5C).
To interrogate the variables for which donors had outlier
events, we plotted the number of donors per feature
(Fig. 5C). Interestingly, liver function tests (e.g., ALT,
GGT, BILI) and circulating immune cell counts (e.g., EOS,
NEUTR, BASO) were highly represented among the feature
space. We also observed higher numbers of donors (N15)
with outlier TRIGLY and IGE levels. Selected variables were
re-tested in the 500 donors sampled at V2, allowing the
evaluation of repeatability. As shown, 4 of 8 (50%) of the
donors with elevated numbers of EOS during V1 also showed
higher levels at V2 (Fig. 5E). These data reinforce the added
value of repeat testing for spurious outlier clinical labora-
tory data, but may also indicate the impact of environmen-
tal determinants on transient biochemical or cell number
elevations. Finally, we investigated a possible association
between EOS and IgE concentrations, as both are associated
with allergic phenotypes. In support of the conclusions of the
PCA, EOS count and IgE concentrations showed no correla-
tion among healthy donors.
Our findings collectively help to define and validate the
constitution of a healthy reference population, which will
serve as a foundation for understanding and quantify the
extent to which phenotypic variation in immune responses is
under genetic or environmental control.
4. Discussion
The immune system is responsible for maintaining a healthy
state, preventing infection and maintaining homeostasis.
For some individuals, however, immune dysfunction can
occur and results in increased susceptibility to infections,
inflammation, autoimmunity, allergy or even cancer. More-
over, such individual heterogeneity in the immune response
may have a major impact on the likelihood to respond to
therapy or the development of side effects secondary to
vaccine administration. Most prior studies aiming to under-
stand the extent to which variation in immune responses is
associated with immunopathology sensu lato have taken a
disease-based approach, from which considerable insight
into immune mechanisms have been obtained. Nonetheless,
to utilize this information in diagnosis and disease manage-
ment, the definition of the baseline parameters for immune
function across the human “healthy” population is required.To achieve this goal, the Milieu Intérieur Project aims to
provide a foundation for defining perturbations in an
individual's immune system responses.
The Milieu Intérieur clinical study was designed and
performed in healthy volunteers to develop a diverse sample
collection with wide ranging associated meta-data. Ultimate-
ly, the generation of genetic data (based on genome-wide
genotyping and whole exome sequencing) and multiple
phenotypes (molecular, cellular and organismal) in available
samples of the study cohort will produce a rich data
warehouse. This will allow datamining studies for associations
and consequently increase our knowledge of the different
factors involved in the regulation of immune responses. During
the design of the clinical study, we encountered the challenge
of defining the genuine meaning of being “healthy” according
to rational and measurable parameters. As such, strict criteria
for enrolling donors were established, taking into consider-
ation both recruitment feasibility, and the statistical power
provided by a 1000-persons study, covering 10 strata (segre-
gated across sex and age, by decade). While some exclusion
factors were easy to apply, such as chronic infections (e.g.,
HCV) or severe disease (e.g., cancer, autoimmunity, etc.),
others were more challenging, such as the boundary for
allergic individuals, those that are exposed to known toxins
(e.g., cigarettes), and persons with presyndromic signs (e.g.,
hypertension). Although the use of reference values for
hematological, biochemical and serology parameters, com-
monly accepted in the clinic to define the healthiness of an
individual, was considered as inclusion/exclusion criteria,
there was a concern about the potential loss of extreme
phenotypes. We thus chose cut off values that might indicate
the requirement for medical follow-up (e.g., liver enzyme
concentrations N 3 × ULN). Factors affecting the immune
system and/or the composition of microbiota were also
considered, including pre-term birth, current and prior
exposure to medical treatments (e.g., aspirin), or the use of
homeopathic medicaments (e.g., essential oils). Ultimately,
we settled on the allowance of parameters expected to be
present in N5% of the sampled individuals, and excluded any
condition that necessitated past or current medical treat-
ment. Detailed personal and family medical histories were
systematically recorded, and associated meta-data will be
used to define genetic, immunologic, and enterotype associ-
ations; and/or to regress out potential confounding factors.
We hope that this set of criteria will help the international
community taking steps towards a consensus definition of a
healthy status for immunologic studies.
In considering selection biases linked to cross-sectional
population-based studies [13], we consider several potential
sources. The primary sources of selection bias are selective
survival with fixed exposure in time (e.g., older donor survival
effect); and non-fixed exposure in time (e.g., smoking, diet,
alcoholic intake, professional exposure are variable in time).
With respect to the survival effect bias, we in fact see this as
an opportunity, as evidence for an age-associated narrowing
of immunologic, genetic and enterotype variation may point
towards a core signature of healthy status. To address
non-fixed exposure, we highlight that our complete question-
naires provide an overview of both current and past
exposures/habits. An additional caveat is that the healthy
volunteers were selected from a pre-existing donor database,
curated by a Clinical Research Organization. These volunteers
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recruitment strategy may also explain the higher percentage
of out-of-work persons, and the higher level of education as
compared to the local Ille-et-Vilaine population.
Following our initial validation of known associations of
health and clinical laboratory/immunological parameters,
we investigated correlates with the metabolic syndrome
index score. Among the general adult population, it is
estimated that 20–25% meet the criteria for having
metabolic syndrome (index score ≥ 3), so the identification
of risk factors is central to establishing public health
initiatives. While metabolic syndrome has been carefully
evaluated in the context of disease settings, few studies
have investigated healthy donors for risk factors. Interest-
ingly, in a “healthy” setting, our study revealed that sex
(i.e., being a man), aging and active cigarette smoking are
each independent risk factors for an elevated metabolic
score index. While epidemiological data support our findings
for men and age as associated risk factors, the evidence for
smoking as an independently associated variable (i.e.,
measured after regressing out sex and age) has been so
far controversial. Our data indicate that four of the six
individual component biologic variables are not statistically
different for smokers as compared to non-smokers, however
the global score supported its association with metabolic
syndrome. Previous published studies, focusing primarily on
individuals presenting overweight and obesity, showed an
additive effect for smoking as an associated risk factor [14].
Conversely, other studies have failed to detect such
associations and at least one study conducted among Turkish
women found a protective effect of smoking on metabolic
syndrome [15]. This has been attributed in part to the use of
different definitions of metabolic syndrome. A recent
meta-analysis evaluated data from 13 prospective studies for
which primary data was available (n = 56,691 participants
overall), and in a dose-response analysis, active smoking
habits was positively associated with risk of metabolic
syndrome (pooled relative risk [RR] = 1.26, 95% CI: 1.1–1.44)
[16]. Our results, which differ from previous studies in that
they are based on healthy donors, provide additional
support for their findings and are consistent with experi-
mental data indicating that cigarette smoking modifies
hormone levels (e.g., cortisol), which in turn may result in
the establishment of a more “insulin-resistant” state or
the increase in waist circumference, a result of deposition
visceral fat mass [17].
Our investigations of the metabolic syndrome score in
healthy donors also revealed a troubling sex-bias. With the
sole exception of HDL levels, the reference values for women
and men have differing cut-values. For abdominal circumfer-
ence, the effects are dramatic with nearly 60% women being
considered above the threshold value as compared to 27% for
men. Given the wide application of the metabolic syndrome
score since 2001 [18], we suggest that the threshold values be
adjusted for sex-associated differences. Notably, this has
been done in USA populations, however it must be considered
whether the adjusted thresholds have been set based on a
shared definition of health, or instead due to the epidemic of
obesity that is currently raging in first-world countries. Indeed
these indicators impact public health initiatives and treat-
ment endpoints, and therefore must be properly calibrated
and correlated to real endpoints of health and disease. It isour hope that the Milieu Intérieur project will contribute to
the identification of genetic, enterotype and immune re-
sponse associations to metabolic score and other health
indicators, possibly leading to the innovation of personalized
algorithms.
Cytomegalovirus (CMV) infection is one of the most
common infections of the general population [19], with a
seroprevalence of 43% in Europe [20] and 50% in the US [21].
CMV is known to be transmitted through direct contact with
infected bodily fluids, including urine, saliva, tears, but also
blood and semen. A large number of studies have evaluated
risk factors for CMV infection among pregnant women, but
few have studied CMV incidence in a well-defined healthy
donor population. We confirm that being single is an
important risk factor for men and women, due to an
increased number of partners [22], while having children
has no direct impact. This challenges the notion that CMV
transmission often occurs from children to adults and we
suggest instead that adult-to-adult transmission is more
common. Longitudinal studies will be required to confirm
these observations, and to confirm that exposure to children
varies with marital status. We identified another factor
of interest: the consumption of raw vegetables. To our
knowledge, this habit has not been previously described as
a risk factor for CMV infection, and challenges the view that
CMV is mainly transmitted by direct contact. Interestingly,
recommendations to prevent infection usually include the
avoidance of food sharing with young children [23]. While
this might suggest that indirect contact is a risk factor,
there had been little evidence to support this public health
measure. One study has evaluated the duration of CMV
viability on environmental surfaces and found that the virus
could remain viable for 6 h on wet surfaces, including
crackers [24]. Together, our observation supports that CMV
transmission from food sharing has been underestimated
and should be thoroughly evaluated in order to adapt
preventive behaviors.
Interestingly elderly donors in our cohort showed a higher
percentage (44%) of CMV negative individuals than previously
reported studies (20–30% CMV- for N60 years old) [20]. This
likely reflects the “healthy” status of our donors, as defined by
stringent inclusion criteria, in contrast with previous studies
that were performed on the general population. This is also
reflected across the entire cohort, which was 64.8% CMV-,
higher than other reported studies in both Europe (43%) [20]
and the US (50%) [21]. Identifying host and environmental
factors that may lead to increased resistance to CMV infection
throughout life could have major implications for cardiovas-
cular disease, sepsis and healthy aging.
To summarize, our study outlined herein provides an
initial overview of the Milieu Intérieur cohort, which we
believe constitutes a rich source of information and
materials that will ultimately help to characterize and
define topics relating to immunity, genetics, environment
and lifestyle behaviors.
Supplementary data to this article can be found online at
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